◈ Nootpedia
Compact view
Research pass: medium Pharmaceutical · Oral SKIP-FOR-NOW HIGH

Mydayis

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

Same MAS chemical as Adderall plus a 16-hour duration that is uniquely incompatible with Dylan's late chronotype (sleep onset destruction is the central differentiator from IR/XR) — confidence is HIGH (rather than MEDIUM like parent Adderall) because the duration mismatch alone is a categorical disqualifier independent of the parent skip rationale. Verdict would flip only with a clinical ADHD diagnosis AND a chronotype that tolerates 16-hour stimulant exposure.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    All Adderall skip rationale applies (brain-dev concern, no ADHD diagnosis, no healthy-adult cognitive enhancement signal, appetite suppression vs MMA calories, dependence trajectory, sourcing risk). *Plus* the 16-hour duration is the worst possible match for a late chronotype. Dylan currently sleeps at 2-3 AM and is migrating toward midnight — even an early-morning Mydayis dose at 7 AM would maintain therapeutic levels through 11 PM, materially compromising the chronotype migration project itself. HIGH confidence (vs Adderall's MEDIUM) because the duration mismatch alone is categorically disqualifying independent of the parent rationale.

  • 30-50, executive maintenance with clinical ADHD + 14+ hour work day + early-bird chronotype
    OPTIONAL

    ADD with clinical diagnosis only. This is Mydayis's natural population — the executive who wakes at 5-6 AM, dose at 6 AM, needs focus through 8-10 PM, normal early sleep. For this profile only, Mydayis edges out Adderall XR for duration. For everyone else: parent Adderall XR or Vyvanse is the better pick.

  • 50+, mild cognitive decline
    SKIP

    Cardiovascular risk profile is wrong, sleep impact compounds with age-related sleep changes.

  • Anxiety-prone
    HARD SKIP

    16-hour anxiogenic exposure is worse than 4-6hr IR.

  • High athletic load, tested status
    SKIP

    (WADA-banned in-competition). Untested status: still SKIP — appetite suppression through dinner + sleep disruption + extended evening CV load are uniquely bad for daily-training combat athletes.

  • Sleep-disordered (insomnia, late chronotype, shift work)
    HARD SKIP

    The 16-hour duration is categorically incompatible with any sleep architecture concern. Insomnia is the #1 reason Mydayis is discontinued in trials.

  • DylanLate chronotype migrating to earlier bedtime (Dylan)
    HARD SKIP

    Mydayis would actively sabotage the chronotype migration project.

  • Recovery-focused (post-injury, post-illness)
    SKIP

    Catabolic, appetite-suppressing through dinner, sustained CV load — opposite of recovery requirements.

  • Strength/anabolic-focused
    SKIP

    Appetite suppression through dinner directly opposes calorie/protein targets.

▸ Subjective experience (deep)

Onset: First effects ~1 hour (IR bead). Plateau by 3-4 hours.

Plateau: 4-12 hours of relatively steady effect — smoother than Adderall IR or XR per user reports because the second and third beads kick in as the first fades, preventing a single peak-then-decline curve.

Late effect: 12-16 hours post-dose, gradual taper. Most users still feel meaningful CNS amphetamine effect at 14 hours post-dose — i.e., a 7 AM dose still has appetite-suppressing, sleep-disrupting effect at 9 PM.

Crash: Typically less pronounced than IR, partly because the taper is so gradual that the body never gets a sharp "off" signal — but this means the comedown is replaced by subtle persistent over-arousal extending into bedtime.

Sleep impact: Reliably reported as worse than other MAS formulations. Sleep onset latency increased 30-90 minutes in many users vs Adderall XR; total sleep time reduced 30-60 minutes; subjective sleep quality reduced.

Characteristic effects:

  • Same as Adderall: drive, motivation, narrowed sustained attention, mood lift, appetite suppression, jaw clenching, BP/HR elevation, dry mouth, increased confidence (often disconnected from objective performance)
  • Plus the unique "still amped at 8-9 PM" signature
▸ Tolerance + cycling deep dive
  • Tolerance buildup: Fast and meaningful — same as parent Adderall. Cross-tolerant with all amphetamines (Vyvanse, Dexedrine, Adderall IR/XR, Evekeo).
  • Cycling: ADHD clinical practice often runs continuous daily. The 16-hour duration makes "5-on-2-off" partially impractical because bead 3 effects from Friday are still affecting Saturday morning sleep — making weekend washouts less clean than with IR.
  • Reset protocol: 2-4 week complete washout, same as Adderall.
  • Cross-tolerance: Substantial with all amphetamines; partial with methylphenidate; minimal with modafinil.
▸ Stacking deep dive

Synergistic with

  • Same as Adderall: l-theanine, magnesium glycinate/threonate, citicoline (all already in Dylan's V4) — but stacking is moot given SKIP verdict.

Avoid stacking with

  • MAOIs (hypertensive crisis — absolute contraindication)
  • Selegiline >10 mg (loses MAO-B selectivity)
  • Other stimulants (methylphenidate, modafinil, high-dose caffeine — cumulative CV load)
  • MDMA, methamphetamine, cocaine (severe NT system overload, neurotoxicity, cardiac event risk)
  • SSRIs (especially fluoxetine, paroxetine — strong CYP2D6 inhibitors raise amphetamine exposure)
  • Tramadol, dextromethorphan (serotonin syndrome)
  • Yohimbine, ephedrine, high-dose synephrine (sympathomimetic stacking)
  • Acidifying agents (high-dose vit C, ammonium chloride — accelerate renal clearance, blunt effect unpredictably)
  • Alkalinizing agents (bicarbonate, antacids — slow renal clearance, prolong/intensify unpredictably — especially problematic with three-bead delivery because PPI/antacid use can also disrupt the pH-dependent enteric coatings, releasing all three beads early and converting Mydayis effectively into a high-dose Adderall IR)

Neutral / safe co-administration

  • Most of Dylan's V4 stack would be neutral if Mydayis were ever used (it won't be).
▸ Drug interactions deep dive

Same as Adderall — see adderall.md for full detail. Key points:

  • CYP2D6 substrate — PMs (7-10% of Caucasians, awaiting Dylan's 23andMe results) have higher exposure
  • Renal excretion is major route — pH-sensitive (as above)
  • Half-lives: d-amphetamine ~10 hr, l-amphetamine ~13 hr — driving the 16-hr Mydayis duration along with the staged release

Mydayis-specific interaction concern: PPIs and H2 blockers. Because Mydayis relies on intact enteric coatings dissolving at duodenal/distal-small-bowel pH thresholds, acid-suppressing drugs can disrupt the timed release and cause earlier-than-intended dumping of bead 2 and bead 3 — converting the smooth 16-hr profile into something closer to a single high-dose Adderall IR pulse. FDA labeling notes this. Patients on omeprazole, esomeprazole, lansoprazole, famotidine should be evaluated case-by-case; many practitioners pick a different formulation rather than navigate this.

▸ Pharmacogenomics

Same as Adderall — see adderall.md:

  • CYP2D6 (rs3892097, rs1065852) — major determinant of clearance
  • DAT1 / SLC6A3 VNTR (rs28363170, 9R/10R) — stimulant response phenotype
  • DRD4 7R — novelty-seeking, ADHD susceptibility
  • COMT Val158Met (rs4680) — Met/Met more anxiety-prone on amphetamines

Note vs methylphenidate-class: Methylphenidate-class drugs depend on CES1 (carboxylesterase 1) for hydrolysis, which has its own polymorphism profile. Amphetamines (including Mydayis) depend mostly on CYP2D6 — generally lower-impact polymorphism than CES1's effect on methylphenidate, but still meaningful for PMs.

Awaiting Dylan's 23andMe results (June 2026) for direct CYP2D6 status — though for Mydayis specifically this is academic given the SKIP verdict.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx (insurance) Local pharmacy (Takeda — branded only) $400-600/mo cash; copay variable High where stocked No generic as of 2026 — patent-protected (Takeda holds composition + delivery patents). Generic Mydayis not anticipated until late 2027 / 2028.
US Rx (manufacturer assistance) Takeda Help at Hand patient assistance Variable Medium Income-qualified program; does not solve cash-pay for a self-funded user.
US telehealth Schedule II Done, ADHD Online, Klarity, Talkiatry $0-200/mo + Rx cost Medium Same DEA Schedule II telehealth restrictions as Adderall — synchronous video visit + qualifying clinician + legitimate ADHD DSM-5 diagnosis.
Gray market Various darknet Variable / risky Low — DO NOT Schedule II illicit possession = federal felony. Counterfeit risk extremely high; fentanyl/methamphetamine contamination documented in 2023-2025 DEA seizures.
WADA testing N/A N/A N/A Banned in-competition (S6 stimulant). Detectable 2-4 days post-dose in urine.

Cost note: Mydayis is roughly 2-3× the cost of brand-name Adderall XR and ~10× the cost of generic Adderall IR. Without an insurance plan that covers the brand, cash pay is $400-600/month — among the most expensive ADHD stimulant options on the US market. The price-to-marginal-benefit ratio over Adderall XR is unfavorable for most patients even with proper indication.

For Dylan: SKIP entirely. Even if he had a clinical ADHD diagnosis (he does not), the chronotype mismatch + cost premium would push toward Adderall IR or Vyvanse first.

▸ Biomarkers to track (deep)

Same as Adderall — see adderall.md. Mydayis-specific additions:

  • Sleep onset latency tracking (subjective + Oura-style ring) — the primary differentiated side effect
  • Evening BP/HR — sustained CV load through evening hours warrants 9-10 PM home cuff readings, not just morning baseline
  • Appetite VAS at dinner — the differentiated metric vs IR/XR

Given the SKIP verdict for Dylan, this section is academic.

▸ Controversies / open debates Live debate

1. "Three-bead delivery is meaningfully smoother than Adderall XR's two-bead system."

  • Partially true. PK studies show Mydayis maintains more stable plasma amphetamine levels through hours 6-12 than Adderall XR. But: the "smoothness" claim is most relevant to ADHD symptom control (where steady occupancy of dopamine signaling matters); for healthy-adult cognitive enhancement, the marginal smoothness benefit is diluted in a population where the drug doesn't enhance objective cognition meaningfully in the first place.

2. "16-hour duration is a feature, not a bug — for the right user."

  • True for the executive 14-hour-workday early-chronotype user. False for nearly everyone else, especially anyone with sleep architecture concerns or chronotype mismatch. Mydayis is the most narrowly indicated MAS formulation. This narrow indication is a feature for the clinician but a flag for everyone outside the indication.

3. "If Adderall is SKIP for Dylan, does Mydayis even need its own file?"

  • Worth addressing. Yes, because the duration profile is meaningfully different and the verdict-confidence is meaningfully higher than the parent (HIGH vs MEDIUM). The parent Adderall verdict has a "with diagnosis it might flip" exit; the Mydayis verdict, for Dylan specifically, doesn't even have that exit because the chronotype mismatch survives the diagnosis question. Documenting the categorical disqualifier in its own file makes future re-evaluation faster.

4. "Cost premium without a generic — does anyone use it long-term?"

  • Real concern. Mydayis market share is small relative to Adderall XR or Vyvanse, partly due to cost, partly due to insomnia rate. The natural-fit population is real but small. Most prescribers reach for Vyvanse first (12-14 hr, cleaner profile, prodrug → lower abuse liability, generic available since 2023).
▸ Verdict change log
  • 2026-05-06 — Initial verdict: SKIP-FOR-NOW / HIGH CONFIDENCE. Same MAS chemical as Adderall, so all parent skip rationale applies (brain-dev concern at 20, no ADHD diagnosis, no healthy-adult cognitive enhancement signal, appetite suppression, dependence trajectory, sourcing risk). Plus 16-hour duration is categorically incompatible with Dylan's late chronotype + chronotype migration project + MMA athletic profile (extended evening CV load, appetite suppression through dinner). HIGH confidence because the duration mismatch alone disqualifies independent of parent rationale. Verdict would not flip even with a clinical ADHD diagnosis — Vyvanse or Adderall IR would be picked first for chronotype reasons. Encyclopedia entry (2026-05-05) classified Mydayis under amphetamine class with parent SKIP-FOR-NOW; this file confirms and tightens to HIGH confidence specifically due to duration mismatch.
▸ Open questions / gaps Open
  1. Generic Mydayis timing. Patent expirations and generic entry timing don't change the verdict for Dylan but would shift the cost analysis for the natural-fit executive population. Current expectation: late 2027 / 2028.
  2. Comparative head-to-head data for Mydayis vs Vyvanse in adult ADHD is limited. Both are long-acting amphetamines targeting the executive 12-16 hour workday, but Vyvanse has cleaner abuse-deterrent properties (prodrug — must be enzymatically converted from lisdexamfetamine to dextroamphetamine, capping subjective rush even with insufflation). Most clinicians pick Vyvanse first; Mydayis is third-line behind Vyvanse and Adderall XR.
  3. Long-term cardiovascular outcomes specific to 16-hour daily exposure — not yet differentiated from shorter-acting amphetamines in published data. Theoretically should be at least as bad as Adderall given higher daily AUC.
  4. Reset baseline at 25-26. Same as Adderall — revisit verdict when PFC maturation completes. Even at that point, the duration mismatch with late chronotype would persist unless chronotype shifts substantially.
▸ Sources (full, with our context)
Back to compact view